windhz_3o3:Celgene sees EPS as high as $9.17 for 2019.
Celgene (NASDAQ:CELG) announces that it achieved its previously announced 2018 full-year guidance. Outlook for this year:
Revenue: $17.0B - 17.2B; EPS: $8.48 - 9.17; non-GAAP EPS: $10.60 - 10.80.
Product sales: Revlimid: ~$10.8